JP2021513517A5 - - Google Patents
Info
- Publication number
- JP2021513517A5 JP2021513517A5 JP2020541872A JP2020541872A JP2021513517A5 JP 2021513517 A5 JP2021513517 A5 JP 2021513517A5 JP 2020541872 A JP2020541872 A JP 2020541872A JP 2020541872 A JP2020541872 A JP 2020541872A JP 2021513517 A5 JP2021513517 A5 JP 2021513517A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- radiochemotherapy
- composition according
- pharmaceutical composition
- osimertinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023087054A JP2023116537A (ja) | 2018-02-12 | 2023-05-26 | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629166P | 2018-02-12 | 2018-02-12 | |
| US62/629,166 | 2018-02-12 | ||
| PCT/EP2019/053311 WO2019155059A1 (en) | 2018-02-12 | 2019-02-11 | Osimertinib for use in the treatment of non-small cell lung cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023087054A Division JP2023116537A (ja) | 2018-02-12 | 2023-05-26 | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513517A JP2021513517A (ja) | 2021-05-27 |
| JP2021513517A5 true JP2021513517A5 (https=) | 2022-02-16 |
Family
ID=65443828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541872A Pending JP2021513517A (ja) | 2018-02-12 | 2019-02-11 | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
| JP2023087054A Pending JP2023116537A (ja) | 2018-02-12 | 2023-05-26 | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023087054A Pending JP2023116537A (ja) | 2018-02-12 | 2023-05-26 | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20200368231A1 (https=) |
| EP (2) | EP4431154A3 (https=) |
| JP (2) | JP2021513517A (https=) |
| KR (2) | KR20200119243A (https=) |
| CN (2) | CN116870008A (https=) |
| AU (2) | AU2019219304A1 (https=) |
| BR (1) | BR112020015507A2 (https=) |
| CA (1) | CA3090010A1 (https=) |
| EA (1) | EA202091841A1 (https=) |
| IL (1) | IL276406A (https=) |
| MA (1) | MA51823A (https=) |
| MX (1) | MX2020008395A (https=) |
| SG (1) | SG11202007414XA (https=) |
| TW (2) | TWI868714B (https=) |
| WO (1) | WO2019155059A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3133766A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
| CN110433296A (zh) * | 2019-08-16 | 2019-11-12 | 哈尔滨医科大学 | 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用 |
| WO2021148396A1 (en) * | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2022120197A1 (en) * | 2020-12-03 | 2022-06-09 | Emory University | Combinations of epidermal growth factor receptor inhibitors and sterol regulatory element-binding protein inhibitors for uses in cancer therapies |
| WO2022166794A1 (zh) * | 2021-02-02 | 2022-08-11 | 贝达药业股份有限公司 | 埃克替尼在非小细胞肺癌术后辅助治疗中的应用 |
| US20240226101A1 (en) * | 2021-04-30 | 2024-07-11 | Suzhou Puhe BioPharma Co., Ltd. | Pyrimidinylaminobenzenes for lung cancer treatment |
| CN114917231A (zh) * | 2022-05-27 | 2022-08-19 | 杭州师范大学 | β-榄香稀和奥希替尼药物组合在制备抗肺癌药物上的应用 |
| KR102899565B1 (ko) | 2023-02-14 | 2025-12-11 | 박주현 | 좁은 전시공간에서 전시품의 360도 실감 영상투사식 전시장치 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4119551A1 (en) | 2011-07-27 | 2023-01-18 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| EP3191523B1 (en) * | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| WO2016164217A1 (en) * | 2015-04-09 | 2016-10-13 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
| WO2017164887A1 (en) * | 2016-03-25 | 2017-09-28 | OSI Pharmaceuticals, LLC | Pulse dosing regimen and methods for treatment |
| US10813933B2 (en) * | 2016-05-17 | 2020-10-27 | Japanese Foundation For Cancer Research | Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance |
| US20200038398A1 (en) * | 2017-03-10 | 2020-02-06 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
-
2019
- 2019-02-11 JP JP2020541872A patent/JP2021513517A/ja active Pending
- 2019-02-11 TW TW112120315A patent/TWI868714B/zh active
- 2019-02-11 CN CN202310971255.1A patent/CN116870008A/zh active Pending
- 2019-02-11 EP EP24173629.7A patent/EP4431154A3/en active Pending
- 2019-02-11 EA EA202091841A patent/EA202091841A1/ru unknown
- 2019-02-11 SG SG11202007414XA patent/SG11202007414XA/en unknown
- 2019-02-11 KR KR1020207022313A patent/KR20200119243A/ko not_active Ceased
- 2019-02-11 TW TW108104348A patent/TW201941773A/zh unknown
- 2019-02-11 MA MA051823A patent/MA51823A/fr unknown
- 2019-02-11 KR KR1020257043592A patent/KR20260009945A/ko active Pending
- 2019-02-11 MX MX2020008395A patent/MX2020008395A/es unknown
- 2019-02-11 WO PCT/EP2019/053311 patent/WO2019155059A1/en not_active Ceased
- 2019-02-11 US US16/968,912 patent/US20200368231A1/en not_active Abandoned
- 2019-02-11 BR BR112020015507-1A patent/BR112020015507A2/pt unknown
- 2019-02-11 EP EP19705720.1A patent/EP3752153A1/en not_active Withdrawn
- 2019-02-11 CN CN201980012384.XA patent/CN111683663A/zh active Pending
- 2019-02-11 AU AU2019219304A patent/AU2019219304A1/en not_active Abandoned
- 2019-02-11 CA CA3090010A patent/CA3090010A1/en active Pending
-
2020
- 2020-07-30 IL IL276406A patent/IL276406A/en unknown
-
2021
- 2021-10-27 US US17/512,153 patent/US20220184076A1/en not_active Abandoned
-
2022
- 2022-05-05 AU AU2022203007A patent/AU2022203007B2/en active Active
-
2023
- 2023-03-28 US US18/191,219 patent/US20230226059A1/en not_active Abandoned
- 2023-05-26 JP JP2023087054A patent/JP2023116537A/ja active Pending
-
2024
- 2024-01-16 US US18/413,349 patent/US20240156815A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513517A5 (https=) | ||
| JP2021098728A5 (https=) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2014512356A5 (https=) | ||
| JP2015523397A5 (https=) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2019517542A5 (https=) | ||
| JP2014532704A5 (https=) | ||
| JP2011511071A5 (https=) | ||
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| JP2021080296A5 (https=) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2017533220A5 (https=) | ||
| JP2022526159A5 (https=) | ||
| Swapnil et al. | Targeted Drug Delivery: A Backbone for Cancer Therapy | |
| Starling et al. | A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma | |
| CA2554463C (en) | Anti-cancer therapies | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| JP2020520385A5 (https=) | ||
| JP2011500650A5 (https=) | ||
| JP2016522826A5 (https=) | ||
| JP2024520307A5 (https=) | ||
| CN110891574B (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| JP2023538186A (ja) | 化学療法誘発性下痢を治療するための方法及び組成物 |